Consistent with the marked reduction of hepatic fibrosis by gemigliptin, TNFα and IL1B were significantly lower in the liver and plasma of the gemigliptin-treated group than in the MCD diet–fed group (Figure 2H,I). This evidence concerns the gene IL1B and Hepatic fibrosis.